PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2929366-1 1989 Formation of inositol phosphates in response to carbachol, phenylephrine and vasoactive intestinal polypeptide (VIP) was studied after labelling with [3H]myo-inositol in rat submandibular gland fragments. Tritium 151-153 vasoactive intestinal peptide Rattus norvegicus 77-110 11502355-0 2001 Synergism between A(2A)-adenosine receptor activation and vasoactive intestinal peptide to facilitate [3H]-acetylcholine release from the rat motor nerve terminals. Tritium 103-105 vasoactive intestinal peptide Rattus norvegicus 58-87 11502355-2 2001 Facilitation of [(3)H]-ACh release by VIP (100 nM) only becomes apparent when high frequency (50 Hz) or long lasting pulses (1 ms) were delivered to the phrenic nerve; VIP excitation was prevented by removal of endogenous adenosine tonus, with adenosine deaminase (2.5 units/ml) or with the A(2A)-receptor antagonist, 3,7-dimethyl-1-propargyl xanthine, (10 microM). Tritium 17-21 vasoactive intestinal peptide Rattus norvegicus 38-41 11502355-2 2001 Facilitation of [(3)H]-ACh release by VIP (100 nM) only becomes apparent when high frequency (50 Hz) or long lasting pulses (1 ms) were delivered to the phrenic nerve; VIP excitation was prevented by removal of endogenous adenosine tonus, with adenosine deaminase (2.5 units/ml) or with the A(2A)-receptor antagonist, 3,7-dimethyl-1-propargyl xanthine, (10 microM). Tritium 17-21 vasoactive intestinal peptide Rattus norvegicus 168-171 9927999-5 1998 In 24-h [3H]thymidine incorporation assay, PACAP or VIP exhibited a suppressive effect on the DNA synthesis of rat VSMC stimulated by serum when added at the late G1 phase. Tritium 9-11 vasoactive intestinal peptide Rattus norvegicus 52-55 18054436-0 2008 A1 and A2A receptor activation by endogenous adenosine is required for VIP enhancement of K+ -evoked [3H]-GABA release from rat hippocampal nerve terminals. Tritium 102-104 vasoactive intestinal peptide Rattus norvegicus 71-74 8543566-6 1995 The addition of phorbol 12-myristate 13-acetate (PMA) or agents elevating the cyclic AMP content, such as vasoactive intestinal peptide (VIP) or an adenosine analog, also stimulated [3H]NA release. Tritium 183-185 vasoactive intestinal peptide Rattus norvegicus 137-140 7475904-8 1995 VIP (500 nM) significantly increased [3H] arachidonate liberation from primary cultures of anterior pituitary cells at 30 min (p < 0.5) and 60 min (p < 0.01), but had no significant effect on the liberation of this fatty acid at 15 or 120 min. Tritium 38-40 vasoactive intestinal peptide Rattus norvegicus 0-3 7475904-11 1995 Similarly, VIP increased [3H] arachidonate liberation from a preparation of anterior pituitary cells enriched in lactotropes. Tritium 26-28 vasoactive intestinal peptide Rattus norvegicus 11-14 8237421-6 1993 Pre-incubation with vasoactive intestinal polypeptide (VIP), which coexists with acetylcholine in the parasympathetic neurons innervating the submandibular gland, increased the carbachol-induced tritium overflow significantly. Tritium 195-202 vasoactive intestinal peptide Rattus norvegicus 20-53 8237421-6 1993 Pre-incubation with vasoactive intestinal polypeptide (VIP), which coexists with acetylcholine in the parasympathetic neurons innervating the submandibular gland, increased the carbachol-induced tritium overflow significantly. Tritium 195-202 vasoactive intestinal peptide Rattus norvegicus 55-58 8237421-7 1993 The effect of VIP could be imitated by the adenylyl cyclase stimulator forskolin, which increased the carbachol-stimulated tritium efflux in a dose dependent manner. Tritium 123-130 vasoactive intestinal peptide Rattus norvegicus 14-17 1327729-2 1992 VIP enhanced [3H]dopamine accumulation dose dependently. Tritium 14-16 vasoactive intestinal peptide Rattus norvegicus 0-3 1327729-4 1992 VIP increased [3H]dopamine accumulation significantly within 15 min. Tritium 15-17 vasoactive intestinal peptide Rattus norvegicus 0-3 2676081-9 1989 Occasional VIP-LI fibres were also labelled with silver grains for [3H]PrBCM, but in less abundance than those for NPY-LI fibres. Tritium 68-70 vasoactive intestinal peptide Rattus norvegicus 11-14 2929366-1 1989 Formation of inositol phosphates in response to carbachol, phenylephrine and vasoactive intestinal polypeptide (VIP) was studied after labelling with [3H]myo-inositol in rat submandibular gland fragments. Tritium 151-153 vasoactive intestinal peptide Rattus norvegicus 112-115 3123488-9 1988 The effect of VIP on [3H]IP, [3H]IP2, and [3H]IP3 production was reduced by (1 to 30 microM) VIP antagonist (an analogue of growth hormone-releasing factor, Ac-Tyr1hGRF) and 1 to 20 microM naloxone. Tritium 22-24 vasoactive intestinal peptide Rattus norvegicus 14-17 3123488-9 1988 The effect of VIP on [3H]IP, [3H]IP2, and [3H]IP3 production was reduced by (1 to 30 microM) VIP antagonist (an analogue of growth hormone-releasing factor, Ac-Tyr1hGRF) and 1 to 20 microM naloxone. Tritium 30-32 vasoactive intestinal peptide Rattus norvegicus 14-17 3123488-9 1988 The effect of VIP on [3H]IP, [3H]IP2, and [3H]IP3 production was reduced by (1 to 30 microM) VIP antagonist (an analogue of growth hormone-releasing factor, Ac-Tyr1hGRF) and 1 to 20 microM naloxone. Tritium 30-32 vasoactive intestinal peptide Rattus norvegicus 93-96 3123488-9 1988 The effect of VIP on [3H]IP, [3H]IP2, and [3H]IP3 production was reduced by (1 to 30 microM) VIP antagonist (an analogue of growth hormone-releasing factor, Ac-Tyr1hGRF) and 1 to 20 microM naloxone. Tritium 30-32 vasoactive intestinal peptide Rattus norvegicus 14-17 3123488-9 1988 The effect of VIP on [3H]IP, [3H]IP2, and [3H]IP3 production was reduced by (1 to 30 microM) VIP antagonist (an analogue of growth hormone-releasing factor, Ac-Tyr1hGRF) and 1 to 20 microM naloxone. Tritium 30-32 vasoactive intestinal peptide Rattus norvegicus 93-96 2826690-2 1988 The exposure of rat hippocampal slices to VIP increased [3H]acetylcholine ([3H]ACh) synthesis from the precursor [3H]choline when tissue was incubated in normal or in high K+ medium; the maximal effect was apparent at 10(-8) M VIP and 10(-7) M VIP, respectively. Tritium 57-59 vasoactive intestinal peptide Rattus norvegicus 42-45 6473159-5 1984 The positive effect of VIP on 5-HT release results partially from an inhibition of the reuptake of 5-HT: in male and OVX SCA, VIP inhibited the 3H-5-HT uptake by 40 to 50%. Tritium 144-146 vasoactive intestinal peptide Rattus norvegicus 23-26 6473159-5 1984 The positive effect of VIP on 5-HT release results partially from an inhibition of the reuptake of 5-HT: in male and OVX SCA, VIP inhibited the 3H-5-HT uptake by 40 to 50%. Tritium 144-146 vasoactive intestinal peptide Rattus norvegicus 126-129 6324050-3 1984 We observed nerve terminals showing selective uptake of [3H]serotonin forming synaptic contact with perikarya or dendrites where the postsynaptic structures exhibited VIP-like immunoreactivity in the SCN and ACTH-like immunoreactivity in the AN. Tritium 57-59 vasoactive intestinal peptide Rattus norvegicus 167-170 6655494-4 1983 Scatchard analysis indicates that, in the presence of bacitracin, VIP significantly decreases the affinity and increases the number of specific high affinity binding sites for [3H]5-HT in the dorsal hippocampus. Tritium 177-179 vasoactive intestinal peptide Rattus norvegicus 66-69 2821819-1 1987 The vasoactive intestinal peptide (VIP) induces a concentration-dependent secretion of newly synthesized (3H labeled) proteins from lacrimal gland fragments. Tritium 106-108 vasoactive intestinal peptide Rattus norvegicus 35-38 3737443-9 1986 On the other hand, the increase of the 3H-5-HT in the synaptic cleft, induced by VIP, did not modify the inhibition of 3H-5-HT release induced by 5 nM of exogenous 5-HT. Tritium 39-41 vasoactive intestinal peptide Rattus norvegicus 81-84